Semaglutide 8-week results: what the trial data actually shows

Where week eight sits in the titration schedule

Semaglutide for weight management follows a gradual dose escalation. Treatment opens at 0.25mg weekly for the first four weeks, a level that exists to let the body acclimatise rather than to produce meaningful weight loss. At week five the prescriber moves the dose to 0.5mg, which is where most people find themselves at the eight-week mark. From there, the schedule continues through 1.0mg, 1.7mg and finally 2.4mg, with roughly four weeks at each level.

That context matters when reading eight-week results. The 2.4mg maintenance dose (the level at which the STEP 1 trial recorded its headline figures) is still months away for someone who has just started. Framing week eight as a verdict on whether semaglutide is working misses the point; it is a checkpoint on a longer journey. If you want a fuller picture of how progress typically builds across the whole schedule, the week-by-week semaglutide results guide maps each phase in detail.

What most people do notice at eight weeks is a genuine shift in appetite. Portions feel smaller. The urge to snack eases. That neurological effect, which reflects GLP-1 receptor activity in the brain's satiety pathways, tends to precede significant scale movement. It is a signal the medicine is doing something, even when the number on the scales feels modest. If you are curious how much of that shift is already visible in the early days, reading about typical semaglutide two-week results helps set a realistic baseline for what to expect before reaching eight weeks.

What the clinical evidence recorded at this stage

The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults with obesity or overweight and at least one weight-related condition over 68 weeks. Average weight loss at full maintenance was around 15%. Interim analyses from comparable GLP-1 trials suggest that at roughly the eight-week mark (still on a sub-maintenance dose) participants had typically lost somewhere in the region of 2–4% of body weight, with the rate of loss accelerating as doses increased.

That trajectory is important. Weight loss with semaglutide is not front-loaded; it compounds over time as the dose rises and the body responds to sustained appetite reduction. People who compare their week-eight result to a friend's three-month result are essentially comparing two different stages of the same process. For a broader look at what the full trial evidence shows for Wegovy, the semaglutide results overview covers the complete dataset.

Individual variation is real. Genetics, starting weight, diet quality, activity levels and how well GI side effects have been managed all influence early progress. A slower start at eight weeks does not predict a poor long-term outcome.

Side effects in the first eight weeks and how they typically behave

The first two months are when GI side effects are most likely to be felt. Nausea is the most commonly reported, followed by loose stools, constipation, indigestion and occasional burping. These effects are closely tied to dose changes: many people find the 0.5mg step at week five brings a fresh wave of nausea that eases by week seven or eight. For a practical answer to how long these sensations typically last, this guide to Wegovy symptom duration explains what the evidence shows.

Eating smaller, lower-fat meals, staying well hydrated and not rushing dose increases tends to help. One thing our prescribers hear fairly regularly: people feel discouraged if nausea has been dominant in week six or seven and the scales haven't moved much. Knowing that the two often coincide (the dose is climbing and the gut is adjusting simultaneously) makes the picture less alarming. The NHS semaglutide medicines page sets out the full side-effect profile clearly and is worth bookmarking for reference.

Serious symptoms always warrant prompt medical attention: severe, persistent stomach pain that spreads toward the back can occasionally signal pancreatitis and should not be waited out. Report any unexpected reactions through the MHRA Yellow Card scheme.

What shapes progress beyond week eight

Getting the most from semaglutide over the months following week eight comes down to a few practical factors. Protein intake tends to support lean mass during a calorie deficit, worth thinking about when appetite is reduced and total food volume drops. Strength-based activity has a similar effect. Neither point requires anything elaborate; a bit of planning before the weekly shop is usually enough.

The dose trajectory also continues to matter. People who reach 2.4mg and sustain it for several months see the most substantial results in the trial data. Some find the 1.7mg dose their practical ceiling due to side effects; the prescriber's role is to find the highest tolerated dose, not to insist on the maximum. Decisions about pace, dose and duration are made during clinical review, not self-directed. If you want to understand how the overall treatment timeline fits together, this page on how long Wegovy takes to work gives an honest answer. And if you are curious how the earliest weeks compare to where you might be at eight weeks, the week one data puts the starting point in perspective.

For anyone considering starting treatment, checking your eligibility with our prescribers is the natural next step. A real clinician reads every consultation the same day, not software, not a queue.